News

Getting regular exercise can help improve life quality, ease depression, and minimize the risk of medication side effects in people with newly diagnosed multiple…

Corcept Therapeutics is launching a Phase 2 clinical trial to evaluate the safety and efficacy of relacorilant as a triple combination treatment — with…

Exportin-1, a therapeutic target for nuclear export inhibitors — a class of drugs used to treat blood cancers including multiple myeloma and leukemia…

Blocking the activity of a protein called FGFR2 may prevent some pancreatic cancers  from developing, a study in mice indicated. The study, “…

CAN-2409 (aglatimagene besadenovec), Candel Therapeutics‘ investigational immunotherapy, was safe and demonstrated potential survival benefits in patients with high-grade glioma, an aggressive type of…

Adding relacorilant to standard chemotherapy was shown to extend survival among people with platinum-resistant ovarian cancer, meeting the primary endpoint, or goal, of a…

A CAR T-cell therapy manufactured in mainland China has been successfully deployed for the first time in Hong Kong to treat a man with myeloma,…

The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…

The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of…

Combining VXM01, an experimental anticancer vaccine, with Bavencio (avelumab), which activates the immune system to attack cancer cells, was well tolerated in a…